glp-1 receptor agonists adverse effects of glp-1_analogs [TUSOM | Pharmwiki]

Tirzepatide has the potential to prevent atherosclerosis risk in T2DM patients without pre-existing lesions

6 Similarly, as GLP-1RAs significantly reduced the risk of MACE, mortality from CV causes, when compared with placebo, ADA has suggested that these medications should be used in patients with underlying cardiovascular disease

These differences may also explain differences in gastrointestinal adverse reactions, such as nausea and vomiting, which are common with GLP-1RAs but typically diminish over time [127, 128]

F., & Kahan, S

Hayes, M

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist